A Lyme disease vaccine may finally be on the way. Why did it take so long?
The article says reported Lyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 2025 preliminary cases at 7,105, citing PHAC data. It notes no human Lyme vaccine is currently approved. It describes Pfizer and Valneva’s co-developed vaccine PF-07307405 completing Phase 3 as of March 2026, and Moderna’s mRNA-1975 and mRNA-1982 in Phase 2.
How this was made
The 30-second read
Why it matters
It frames Lyme disease as rising in Canada and ties the renewed vaccine effort to specific programs: Pfizer and Valneva’s PF-07307405 (Phase 3) and Moderna’s mRNA-1975 and mRNA-1982 (Phase 2).
Market read
For traders, the actionable element is the Phase 3 results announcement for PF-07307405, which can shift biotech probability-of-success expectations, while Moderna’s Phase 2 programs are more incremental.
What to watch
The text does not cover regulatory strategy, manufacturing readiness, or whether endpoints met targets, all of which can dominate post-readout price action.
Background
The article notes LYMErix was FDA-approved in 1998 and withdrawn after adverse-reaction reports and weak demand, and that no human Lyme vaccine has been approved since.
Ticker impact
Pfizer is co-developing a Lyme vaccine (PF-07307405) and the article says it announced Phase 3 results in March 2026.
Near-term volatility possible as traders reprice the likelihood of regulatory success and timelines.
The article provides a specific Phase 3 completion and a March 2026 results announcement, which is typically a catalyst for biotech sentiment even without disclosed efficacy/safety numbers.
Valneva is the French biotech partner with Pfizer on PF-07307405, and the article notes Phase 3 results were announced in March 2026.
Potential upside bias if the market interprets the Phase 3 outcome favorably; otherwise downside risk if results are mixed.
The text confirms Phase 3 completion and a results announcement but does not include the actual trial outcomes, limiting precision on direction.
Moderna is developing two Lyme mRNA vaccines (mRNA-1975 and mRNA-1982), both in Phase 2 trials per the article.
Limited immediate impact versus Phase 3 programs, but could support longer-dated pipeline sentiment.
The article provides development-stage information only, with no new trial readouts or guidance.
Market effects
Highlights renewed Lyme vaccine R&D momentum, which can lift sentiment across vaccine and infectious-disease biotech peers.
Canada case-count context may increase attention from North American public health stakeholders, but it is not a direct tradable catalyst.
Lyme disease burden is global; successful late-stage results could influence international vaccine procurement and competitive dynamics.
Counterpoint
Phase 3 “results announced” does not guarantee positive efficacy or acceptable safety, and the article omits the actual data that would drive repricing.
Key entities
- vaccine programPF-07307405
Lyme disease vaccine co-developed by Pfizer and Valneva; the article says Phase 3 trials were completed and results were announced in March 2026.
- vaccine programmRNA-1975
Moderna Lyme vaccine candidate; the article says it is in Phase 2 as of the described timeframe.
- vaccine programmRNA-1982
Moderna Lyme vaccine candidate; the article says it is in Phase 2 as of the described timeframe.
